Healthcare / BiotechnologyNasdaqGM
$11.59
-0.49 (-4.05%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-25.4M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$975M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-25.0%
↓Gross Margin
N/A
•Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
2.16x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-15.3M · FCF $-33.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Net Income | $-15.3M | $-15.3M | $-62.3M | $-27.0M | $-41.3M | $-43.2M | $-6.0M | $-46.7M | $-46.9M | $-55.7M | $-36.4M | $-31.3M | $-161000.00 |
| EBITDA | $-42.9M | $-42.9M | $-27.5M | $-23.3M | $-32.2M | $-38.2M | $-43.1M | $-48.1M | $-48.4M | $-55.7M | $-36.4M | $-13.6M | — |
| EPS | — | — | -1.02 | -0.56 | -0.89 | -1.03 | -0.20 | -1.59 | — | — | — | — | — |
| Balance Sheet | |||||||||||||
| Debt/Equity | 0.02 | 0.02 | 0.03 | 0.04 | 0.05 | — | — | — | — | — | — | — | — |
| Current Ratio | 19.81 | 19.81 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-33.0M | $-33.0M | $-25.4M | $-24.0M | $-27.3M | $-36.7M | $-34.9M | $-37.3M | $-41.3M | $-46.5M | $-30.1M | $-13.1M | — |
| Returns | |||||||||||||
| ROE | -25.0% | -25.0% | -191.3% | -69.9% | -73.6% | -44.5% | -8.3% | -65.6% | -42.5% | -65.6% | -27.4% | 100.8% | 101.3% |
| Valuation | |||||||||||||
| P/B | 14.15 | 14.15 | 10.92 | 2.56 | 0.71 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| EPS Growth | — | — | -82.1% | 37.1% | — | -415.0% | 87.4% | — | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+187.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.02 → n/d
Residual
+187.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.